China leads in clinical trials outside North America and Europe in Q2

Meanwhile, India overtook Iran to claim second place.

China remained the most popular country for clinical trials outside North America and Europe in the second quarter of the year (Q2), according to a report by GlobalData.

India overtook Iran to claim second place, initiating 944 clinical trials compared to Iran’s 348.

The decline in trial activity is attributed to the growing tensions involving Israel, US, and Iran during Q2.

Globally, oncology was the leading therapeutic area of focus, with 1,674 clinical trials launched or scheduled during the quarter. Central nervous system diseases followed with 1,521 trials.

Both categories saw a slight increase from the same period last year, which recorded 1,637 and 1,429 trials, respectively.